Skip to main content

Table 5 Incidence of neutropenia

From: Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial

  EP (n = 425) TPC (n = 406)
Number of patients with neutropenia, n (%) 111 (26.1) 174 (43.1)
 Grade 1–2 70 (16.5) 50 (12.3)
 Grade 3 32 (7.5) 79 (19.5)
 Grade 4 9 (2.1) 45 (11.1)
 Grade 5 0 (0) 1 (0.2)
  1. A composite term encompassing neutropenia, febrile neutropenia, neutropenic sepsis, and neutrophil count decreased